�鶹ֱ�� Advises Swing Therapeutics on Sale to XRHealth

�鶹ֱ�� & Lardner LLP advised , a leading developer of digital therapies, on its sale to , the leading platform for therapeutic technologies.

The acquisition adds Swing Therapeutics’ FDA De Novo-authorized prescription digital behavioral therapeutic Stanza program to XRHealth’s existing behavioral health and chronic pain capabilities, deepening the platform’s reach into two of the most underrated conditions in the country: fibromyalgia and chronic pain. The combined infrastructure deploys across VR glasses, smartphones, and wearables to deliver continuous, personalized whole-patient care reimbursed via Medicare, VA programs, and commercial insurance pathways.

The �鶹ֱ�� team served as legal counsel for health care regulatory issues and was led by partner Thomas (T.J.) Ferrante, vice chair of the firm’s nationally recognized Health Care Practice Group, and included support from associates Bradley Henson and Chana Gandelsman.

�鶹ֱ��’s Telemedicine & Digital Health Industry Team helps venture-backed and high-growth companies embrace emerging issues in virtual care, enabling them to provide innovative care for patients in new markets around the block and around the world. �鶹ֱ�� is committed to helping entrepreneurs fulfill their goals of harnessing new technology to reach patients anywhere, delivering care without borders or geographic limitations. The firm helps create fully-fledged telemedicine offerings, providing end-to-end legal services by coupling precise strategic guidance with rapid turnarounds to maintain that sense of urgency necessary to launch new initiatives and remain competitive in the marketplace.

Learn more at .